Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism.
We evaluated the neuroprotective potential of tachykinin peptides using a model system in which mesencephalic dopaminergic (DA) neurons die spontaneously and selectively as they mature. The three native tachykinins, substance P (SP), neurokinin (NK) A, and NKB afforded substantial protection against DA cell demise. The selective NK1 receptor antagonist [D-Pro9,[spiro-gamma-lactam] Leu10,Trp11]substance P (GR71251) was sufficient in itself to suppress the effect of SP, whereas a cotreatment with GR71251 and the NK3 receptor antagonist (R)-N-[alpha-(methoxycarbonyl)benzyl]-2-phenylquinoline-4-carboxamide (SB218795) was required to prevent the effects of both NKA and NKB. Consistent with these results, D-Ala-[L-Pro9,Me-Leu8]substance P(7-11) (GR73632), a selective agonist of NK1 receptors and [pro7]-NKB, a selective agonist of NK3 receptors, conferred protection to DA neurons, whereas (Lys3, Gly8-R-gamma-lactam-Leu9)neurokinin A(3-10) (GR64349), which activates specifically NK2 receptors, did not. DA neurons rescued by tachykinins accumulated [3H]DA efficiently, which suggests that they were also totally functional. Neuroprotection by tachykinins was highly selective for DA neurons, rapidly reversed upon treatment withdrawal, and reproduced by but independent of glial cell line-derived neurotrophic factor. Survival promotion by tachykinins was abolished by blocking voltage-gated Na+ channels with tetrodotoxin or N-type voltage-gated Ca2+ channels with omega-conotoxin-MVIIA, which indicates that an increase in neuronal excitability was crucially involved in this effect. Together, these data further support the notion that the survival of mesencephalic DA neurons during development depends largely on excitatory inputs, which may be provided in part by tachykinins.
Salthun-Lassalle
Bénédicte
B
INSERM 679, Bātiment Pharmacie, Hôpital de la Salpêtrière, 47 bd de l'hôpital, 75013, Paris, France.
Traver
Sabine
S
Hirsch
Etienne C
EC
Michel
Patrick P
PP
D000818:Animals; D020864:Calcium Channels, N-Type / Q000502:physiology; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D004298:Dopamine / Q000502:physiology*; D015640:Ion Channel Gating; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects*; D015288:Neurokinin A / Q000494:pharmacology*; D015287:Neurokinin B / Q000494:pharmacology*; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D018042:Receptors, Neurokinin-3 / Q000502:physiology; D015222:Sodium Channels / Q000502:physiology; D013373:Substance P / Q000494:pharmacology*; D013779:Tetrodotoxin / Q000494:pharmacology
D020864:Calcium Channels, N-Type; D018696:Neuroprotective Agents; D018040:Receptors, Neurokinin-1; D018042:Receptors, Neurokinin-3; D015222:Sodium Channels; D013373:Substance P; D013779:Tetrodotoxin; D015288:Neurokinin A; D015287:Neurokinin B; D004298:Dopamine